share_log

This Insider Has Just Sold Shares In PROCEPT BioRobotics

This Insider Has Just Sold Shares In PROCEPT BioRobotics

這位內部人士剛剛出售了PROCEPT BioRobotics的股票
Simply Wall St ·  03/11 06:07

We'd be surprised if PROCEPT BioRobotics Corporation (NASDAQ:PRCT) shareholders haven't noticed that the President, Reza Zadno, recently sold US$428k worth of stock at US$46.67 per share. On the bright side, that sale was only 7.5% of their holding, so we doubt it's very meaningful, on its own.

如果PROCEPT BioRobotics Corporation(納斯達克股票代碼:PRCT)的股東沒有注意到總裁雷扎·扎德諾最近以每股46.67美元的價格出售了價值42.8萬美元的股票,我們會感到驚訝。好的一面是,那次出售僅佔他們持股量的7.5%,因此我們懷疑這本身是否有意義。

PROCEPT BioRobotics Insider Transactions Over The Last Year

PROCEPT 過去一年的生物機器人內幕交易

The Independent Chairman of the Board, Frederic Moll, made the biggest insider sale in the last 12 months. That single transaction was for US$3.1m worth of shares at a price of US$39.25 each. That means that even when the share price was below the current price of US$49.28, an insider wanted to cash in some shares. As a general rule we consider it to be discouraging when insiders are selling below the current price, because it suggests they were happy with a lower valuation. However, while insider selling is sometimes discouraging, it's only a weak signal. This single sale was just 8.9% of Frederic Moll's stake.

董事會獨立主席弗雷德裏克·莫爾進行了過去12個月中最大規模的內幕出售。這筆單筆交易是價值310萬美元的股票,每股價格爲39.25美元。這意味着,即使股價低於當前的49.28美元,內部人士也想套現一些股票。通常,當內部人士以低於當前價格的價格出售時,我們認爲這令人沮喪,因爲這表明他們對較低的估值感到滿意。但是,儘管內幕銷售有時令人沮喪,但這只是一個微弱的信號。此次出售僅佔弗雷德裏克·莫爾股份的8.9%。

Insiders in PROCEPT BioRobotics didn't buy any shares in the last year. The chart below shows insider transactions (by companies and individuals) over the last year. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

去年,PROCEPT BioRobotics的內部人士沒有購買任何股票。下圖顯示了去年的內幕交易(公司和個人)。如果你點擊圖表,你可以看到所有的個人交易,包括股價、個人和日期!

insider-trading-volume
NasdaqGM:PRCT Insider Trading Volume March 11th 2024
納斯達克通用汽車公司:PRCT 內幕交易量 2024 年 3 月 11 日

I will like PROCEPT BioRobotics better if I see some big insider buys. While we wait, check out this free list of growing companies with considerable, recent, insider buying.

如果我看到一些重大的內幕收購,我會更喜歡PROCEPT BioRobotics。在我們等待的同時,請查看這份免費清單,列出了最近有大量內幕收購的成長型公司。

Does PROCEPT BioRobotics Boast High Insider Ownership?

PROCEPT BioRobotics 是否擁有很高的內部所有權?

For a common shareholder, it is worth checking how many shares are held by company insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. It appears that PROCEPT BioRobotics insiders own 2.6% of the company, worth about US$66m. While this is a strong but not outstanding level of insider ownership, it's enough to indicate some alignment between management and smaller shareholders.

對於普通股股東來說,值得檢查一下公司內部人士持有多少股票。通常,內部人士的所有權越高,內部人士長期建立公司的可能性就越大。看來PROCEPT BioRobotics內部人士擁有該公司2.6%的股份,價值約6600萬美元。儘管這是一個強勁但並不突出的內部所有權水平,但這足以表明管理層與小型股東之間有一定的一致性。

So What Does This Data Suggest About PROCEPT BioRobotics Insiders?

那麼,這些數據對PROCEPT生物機器人內部人士有何啓示呢?

Insiders sold PROCEPT BioRobotics shares recently, but they didn't buy any. And even if we look at the last year, we didn't see any purchases. Insider ownership isn't particularly high, so this analysis makes us cautious about the company. So we'd only buy after careful consideration. So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. In terms of investment risks, we've identified 3 warning signs with PROCEPT BioRobotics and understanding these should be part of your investment process.

業內人士最近出售了PROCEPT BioRobotics的股票,但他們沒有購買任何股票。而且,即使我們看看去年,我們也沒有看到任何購買。內部所有權並不是特別高,因此這種分析使我們對公司持謹慎態度。因此,我們只有在仔細考慮後才會購買。因此,這些內幕交易可以幫助我們建立有關股票的論點,但也值得了解這家公司面臨的風險。在投資風險方面,我們已經使用PROCEPT BioRobotics確定了3個警告信號,並了解這些信號應該是您投資過程的一部分。

Of course PROCEPT BioRobotics may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

當然,PROCEPT BioRobotics可能不是最值得購買的股票。因此,您可能希望看到這個免費的高質量公司集合。

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

就本文而言,內部人士是指向相關監管機構報告其交易的個人。我們目前只考慮公開市場交易和私下處置的直接利益,不包括衍生品交易或間接權益。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論